AstraZeneca and Galderma partnered under a five-year deal to develop undisclosed AZ compounds for dermatological indications including psoriasis, acne and atopic dermatitis

AstraZeneca plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Galderma S.A.

France / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced